Sector Alpha Week of 2026-07-31
Sector Alpha — machine-written from the numbers · Data as of 2026-07-31

Saraswati Commercial (India) Ltd

ZSARACOM
Finance & Investments - Others

Saraswati Commercial (India) Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

The sharpest disagreement: annual EPS moved +72.8% against a −5.3% price move — the market has not yet caught up with the delivery.

The price is in a downtrend (54 weeks in) while the P/BV sits at the 70th percentile of its own 7-year range. Underneath, the last four quarters read mixed, with the the net margin at 100.0%. What settles it: whether the price catches up with earnings that have already moved.

Price
₹12,400
−5.3% 1Y
P/BV
1.2×
70th pctile
of its own 7-year range
Revenue (Mar 26)
₹−16.0 Cr
Profit (Mar 26)
₹−16.0 Cr
Net margin
100.0%
+11.5 pp YoY
ROE
9%
FY26
ROA
6.20%
latest
Unverified figures: Some figures on this page come from a second financial-data feed that could not be cross-checked against the primary source — the two do not share enough overlapping reported history to compare. They are drawn, because they are the only evidence there is, and every section carrying one is marked unverified. PEG is the exception: the quarterly curve is not drawn at all. PEG asks what is being paid for growth — both sides of that division come from the source that could not be checked, so it is withheld instead of marked.
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Saraswati Commercial (India) Ltd trades at ₹12,400, in a downtrend and 54 weeks into that stage. That is +7.1% against its own 200-day average. It sits at 58% of a 52-week range of ₹9,209 to ₹14,743. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks.

Today the stock is in a downtrend — week 54 of stage 4, confirmed. At ₹12,400 it trades +7.1% versus its 200-day average and sits at 58% of its 52-week range (₹9,209–₹14,743).

Jul 26: ₹12,400 Weekly closing price (₹) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
+7.1% versus the 200-day line, week 54 of stage 4
Price50-day avg200-day avg
S4S2S4S4₹27,041₹20,412₹13,783₹7,155₹526₹12,400₹11,580Jul 23Apr 24Feb 25Oct 25Jul 26
S4S2S4S4₹27,041₹20,412₹13,783₹7,155₹526₹12,400₹11,580Jul 23Feb 25Jul 26
Beating or trailing, week by week since 2017 Each cell is one week from 2017 to now (371 weeks): the stock's trailing 13-week return minus the NIFTY 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the NIFTY 500 reading is not held.
trailing 13-week return vs the NIFTY 500
Jul 17Jul 26

Against the market, two honest reads. Cumulative: over the last 9.0 years the stock moved +1,47,519% while the NIFTY 500 moved +171% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 5 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation For a bank we price the book, not the earnings: P/BV is what the market pays for each ₹1 of the bank's net worth. A bank below 1× book is priced below the value of what it owns, net of what it owes.

Saraswati Commercial (India) Ltd trades at 1.2× P/BV, at the pricey end of its own range (70th percentile). Its long-run median P/BV is 0.9×, measured across 6.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/BV of 1.2× is at the pricey end of its own range (70th percentile), against a long-run median of 0.9× measured over 6.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

The honest context for that discount: a bank earning about 9% on its equity is worth less per rupee of book, and the market has priced that in rather than overlooked it. The discount closes only if the returns themselves improve.

P/BV 1.2× vs a 0.9× long-run median P/BV, weekly (left axis); book value per share, weekly (right axis). 6.9-year window; brief peaks above 2.7× shown pinned at the top. The book value / share bars are red where the reading is lower than the quarter before.
at the pricey end of its own range (70th percentile)
P/BVMedianBook value / share (quarterly)
2.9×₹11,2912.2×₹8,4681.5×₹5,6450.7×₹2,8230.0×₹0.0×1.20×₹10,333Aug 19Dec 21Aug 23May 25Jul 26
2.9×₹11,2912.2×₹8,4681.5×₹5,6450.7×₹2,8230.0×₹0.0×1.20×₹10,333Aug 19Aug 23Jul 26
P/BV
1.2×
70th percentile of 7y

Why the multiple sits where it does: over the past year book value grew while the price moved −5.3% — the price ran ahead of the book, pushing the multiple up its own range.

The price move, decomposed: over 5y, of the +41.3%/yr price move, ~+45.7%/yr came from book-value growth and ~−4.4 pp from the multiple (compressing). The split is the honest approximate (price return minus book-value growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the book-value line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

03 · Stage: No read

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Saraswati Commercial (India) Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 7 quarters across 1 curve, on partial evidence.

Growth, year by year: revenue +61.3% in FY26, profit +73.6% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn. Turnaround-year spikes shown pinned (▲).
Revenue YoYProfit YoYEPS YoY
2,923%343%2,114%186%1,306%29%497%−129%−312%−286%%%61.3%73.6%FY16FY21FY26
2,923%343%2,114%186%1,306%29%497%−129%−312%−286%%%61.3%73.6%FY16FY21FY26
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. Base-effect spikes shown pinned (▲). A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue accelerating, profit accelerating
RevenueProfitEPS
331%331%219%218%108%105%0.0%−7.8%−115%−121%%%61.3%75.5%58.3%Jun 23Sep 24Mar 26
331%331%219%218%108%105%0.0%−7.8%−115%−121%%%61.3%75.5%58.3%Jun 23Sep 24Mar 26
ROE Annual readings — the quarterly balance-sheet pieces this curve needs are not held for this stock, so the returns read moves once a year and carries less weight in the call.
the return curve, annual readings
ROE
19%15%11%6.2%1.8%%9%FY23FY24FY26
19%15%11%6.2%1.8%%9%FY23FY24FY26
ROE
Rising
latest 9.0% · span 3.0%–18.0%

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; share price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+61.3%+71.5%+34.0%+20.3%
Profit+73.6%+97.2%+34.4%+20.7%
EPS+72.8%+95.1%+31.6%
Share price−5.3%+73.4%+41.3%
04 · 4-Factor Sector Score

4-Factor Sector Score

59.1/100 — rank 5 of 33 in Finance & Investments - Others · 67% evidence confidence

Saraswati Commercial (India) Ltd scores 59.1 out of 100 against the 33 companies it is compared with in Finance & Investments - Others, ranking 5. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 24.8 + 14.9 + 10.6 + 8.8 = 59.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if ROA rolls over or gross NPA rises while sector-relative strength deteriorates.

05 · Revenue

Revenue For a bank, revenue is everything the franchise earns — interest on the loan book plus fee and other income.

Saraswati Commercial (India) Ltd reported ₹−16.0 Cr of income in the Mar 26 quarter. Over 10 years it has compounded at 20.3% a year. The last full year, FY26, came in at ₹121 Cr. The last four reported quarters add to ₹121 Cr.

FY26 revenue came in at ₹121 Cr (+61.3% on the year), capping 10 years at 20.3% compound. The latest quarter (Mar 26) printed ₹−16.0 Cr, null year on year.

FY26 revenue ₹121 Cr (+61.3% YoY) Revenue bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
20.3% a year over 10 years
RevenueYoY growth
1382,923%1042,114%691,306%35497%0−312%₹ Cr%₹12161.3%FY16FY21FY26
1382,923%1042,114%691,306%35497%0−312%₹ Cr%₹12161.3%FY16FY21FY26
Mar 26: ₹−16.0 Cr (null YoY) Quarterly revenue bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Revenue (quarterly)YoY growth
88269%52140%1710%−19−119%−55−248%₹ Cr%₹−16−6.4%Jun 23Sep 24Mar 26
88269%52140%1710%−19−119%−55−248%₹ Cr%₹−16−6.4%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged −30.4% growth against the decade's 20.3% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +61.3% over the last 4 quarters against −3.2%/yr over the last 8 — accelerating; TTM profit +75.5% vs −5.0%/yr — accelerating.

06 · Net margin

Net margin Net margin — what the bank keeps of every ₹100 of revenue after every cost, provision and tax. It is the cleanest single margin we can read for a lender.

Saraswati Commercial (India) Ltd's net margin is 100.0% in the Mar 26 quarter, +11.5 percentage points against the same quarter a year ago. Across 13 fiscal years the net margin has ranged −1,000.0% to 100.0%. The current quarter sits inside that band.

The latest quarter's net margin is 100.0%, +11.5 pp against the same quarter a year ago. Across 13 fiscal years the net margin has ranged −1,000.0%–100.0%.

Why: the numbers show the net margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

FY26: 76.0% Net margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 13-year window.
within a −1,000.0–100.0% band over 13 years
net marginYoY change (pp)
188%1,247%−131%623%−450%0.0%−769%−626%−1,088%−1,250%%%76%5.3%FY14FY20FY26
188%1,247%−131%623%−450%0.0%−769%−626%−1,088%−1,250%%%76%5.3%FY14FY20FY26
Mar 26: 100.0% net margin (+11.5 pp YoY) Quarterly net margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Net profit as a share of total revenue, per quarter.
Net marginYoY change (pp)
102%19%94%8.1%87%−2.6%79%−13%71%−24%%%100%11.5%Jun 23Sep 24Mar 26
102%19%94%8.1%87%−2.6%79%−13%71%−24%%%100%11.5%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Saraswati Commercial (India) Ltd posted a net loss of ₹16.0 Cr in the Mar 26 quarter. Full-year FY26 profit was ₹92.0 Cr. The 10-year compound rate is 20.7%. That loss is 100.0% of the quarter's revenue. The same quarter a year earlier lost ₹23.0 Cr. 3 of the last 12 reported quarters were loss-making.

Mar 26 profit was ₹−16.0 Cr, null year on year. On the full year, FY26 printed ₹92.0 Cr (+73.6%), and the 10-year compound rate is 20.7%.

FY26 profit ₹92.0 Cr (+73.6% YoY) Net profit bars, ₹ Cr (left); YoY growth-% line (right). 11-year window. A bar is red when it is lower than the year before.
20.7% a year over 10 years
Net profitYoY growth
113847%80555%47262%14−31%−19−324%₹ Cr%₹9273.6%FY16FY21FY26
113847%80555%47262%14−31%−19−324%₹ Cr%₹9273.6%FY16FY21FY26
Mar 26: ₹−16.0 Cr (null YoY) Quarterly net profit bars, ₹ Cr (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
71355%42201%1247%−18−107%−47−261%₹ Cr%₹−16−4.8%Jun 23Sep 24Mar 26
71355%42201%1247%−18−107%−47−261%₹ Cr%₹−16−4.8%Jun 23Sep 24Mar 26
08 · Asset quality — the ladder

Asset quality — the ladder Gross NPA is the slice of the loan book where repayments have stopped. Net NPA is what remains after the money already set aside against those loans. Falling is healing; rising is damage arriving.

Loan-book quality history is not available for Saraswati Commercial (India) Ltd, so this section names the gap rather than estimating a ratio. No gross or net non-performing-asset series is filed in a form this page can read, and none is inferred from the profit line. The income, margin and return sections above carry the evidence this business does report.

We do not hold quarterly loan-book quality numbers for this bank, so this section states that plainly rather than working around it.

Why: loan-book quality is the engine room of a bank, and its drivers — slippages, recoveries, provisioning — sit below what we hold for this name; the sections around it carry the reads we can stand behind.

09 · The loan book

The loan book We read the loan book through revenue — when the book grows, revenue grows with it. It is a rough proxy, and we say so: rate moves and fee swings can shift it a few points in any one year.

Saraswati Commercial (India) Ltd's revenue grew +61.3% in FY26 to ₹121 Cr, so the book is growing. The net margin on that income is 100.0%, +11.5 percentage points against a year ago. Interest income is a proxy for the book; rate moves can shift it a few points in any one year.

FY26 revenue was ₹121 Cr, +61.3% on the year, and the latest quarter ran null year on year. The net margin on that revenue is 100.0% this quarter (+11.5 pp YoY) — growth with a widening margin on it.

FY26: revenue ₹121 Cr (+61.3% YoY) with the net margin at 76.0% Revenue by fiscal year, ₹ Cr (bars, left); net margin, % (line, right). 11-year window. A bar is red when it is lower than the year before.
RevenueNet margin
138188%104−131%69−450%35−769%0−1,088%₹ Cr%₹12176%FY16FY18FY21FY23FY26
138188%104−131%69−450%35−769%0−1,088%₹ Cr%₹12176%FY16FY21FY26

The synthesis: a lender compounds when the book grows while the margin holds and the loan book stays clean — gross NPA is the loan-quality read we carry here.

10 · Returns on equity and assets

Returns on equity and assets Two numbers rate a bank: ROE — what it earns on shareholder money — and ROA — what it earns on everything it deploys. ROE above ~13–15% earns its keep; below that, growth builds book slowly.⚠ unverified

Saraswati Commercial (India) Ltd earns a return on equity of 9% in FY26. Its trough over the ladder below was −7% in FY20. On the asset side every ₹100 of the balance sheet earned about ₹6.20, which is the return before leverage is applied.

FY26 ROE came in at 9%, recovered from a FY20 trough of −7%. On assets, the latest reading is about 6.20% — every ₹100 the bank deploys earns roughly ₹6.20 a year. That return is below the bar a bank must clear to compound book value quickly — which is also the honest reason the stock trades where it does.

FY26: ROE 9%, ROA 6.20% Return on equity by fiscal year, % (line, left); return on assets, % (line, right). 13-year window. A lender is judged on ROE and ROA — return on invested capital does not apply to a bank.
up from a FY20 trough of −7%
ROEROA
43%14%29%11%16%8.1%2.7%4.9%−11%1.8%%%9%6.2%FY14FY20FY26
43%14%29%11%16%8.1%2.7%4.9%−11%1.8%%%9%6.2%FY14FY20FY26
Q4 FY26: ROE 9.2% (TTM) Trailing-twelve-month return on equity (left), per quarter, %. Last 12 quarters, anchored to the annual figure.
ROE (TTM)
36%22%7.1%−7.6%−22%%9.2%Q1 FY24Q2 FY25Q4 FY26
36%22%7.1%−7.6%−22%%9.2%Q1 FY24Q2 FY25Q4 FY26

Why ROE moved: profit compounded 20.7% a year over 10 years while the equity base grew more slowly — earnings recovering faster than book value builds is what lifts ROE off a trough.

11 · Debt

Debt

For a bank, borrowings are raw material, not a warning sign — solvency is read through the returns and the loan book. A manufacturer’s debt is a claim against its profits, so the debt-to-equity lens that works everywhere else misleads on a lender and is not applied here.

A manufacturer’s debt is a claim against its profits; a bank’s borrowings are its inventory — money taken in to be lent out. The debt lens that works everywhere else misleads here, so this page does not apply it. The solvency questions for a bank — is the loan book sound, is the equity earning — are read through the loan-book and returns sections above.

12 · Ownership

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Promoters added 2.5 points of Saraswati Commercial (India) Ltd over 8 quarters, the biggest move on the register. That takes promoters to 74.9% of the company. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +2.5 points over 8 quarters to 74.9%.

Why the register moved: promoters drove it (+2.5 points) — steady accumulation by institutions reading the same numbers this page reads.

Fiscal-year ends: promoters +2.5 pts from Mar 24 to Mar 26 Shareholding at each fiscal-year end (March quarter), % of the company. 3 year-ends held.
PromotersPublic
79%64%50%36%21%%74.9%25.1%Mar 24Mar 25Mar 26
79%64%50%36%21%%74.9%25.1%Mar 24Mar 25Mar 26
Promoters added 2.5 points over 8 quarters Shareholding by holder class, % of the company, quarterly, last 13 quarters.
PromotersPublic
79%64%50%36%21%%74.9%25.1%Jun 23Dec 24Jun 26
79%64%50%36%21%%74.9%25.1%Jun 23Dec 24Jun 26
13 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Saraswati Commercial (India) Ltd: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre. The Z-score was built for manufacturers and is not applied to banks and lenders, so solvency here is read from the capital and asset-quality lines instead.

The safety line in one sentence: the Z-score is omitted — it was built for manufacturers, not banks, and applying it here would be theatre.

14 · Related companies · Finance & Investments - Others
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Consolidated Finvest & Holdings LtdCONSOFINVT 66.8/100Favorable setup75% evidence BREAKING OUT 15.1/35 Income 31.4% · PAT -30.2% 51% evidence 18.6/25 ROA 5.9% · ROE 33.6% · GNPA — 68% evidence 13.7/20 P/BV 0.61× · P/BV÷ROE 0.02 100% evidence 19.4/20 RS sector 46% · RS bench 42.3% · 1Y 46.7%5 of 12 weeks ahead 100% evidence
Exact sum: 15.1 + 18.6 + 13.7 + 19.4 = 66.8 · Decision use: Price leads the evidence: RS versus the benchmark is 42.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
2Fedders Holding LtdFEDDERSHOL 65.5/100Favorable setup76% evidence BREAKING OUT 24.5/35 Income -18.8% · PAT 100% 71% evidence 18.0/25 ROA 10.9% · ROE 11.6% · GNPA — 68% evidence 13.5/20 P/BV 1.18× · P/BV÷ROE 0.1 70% evidence 9.5/20 RS sector -4.5% · RS bench -8.1% · 1Y -6.9%6 of 12 weeks ahead 100% evidence
Exact sum: 24.5 + 18 + 13.5 + 9.5 = 65.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Gretex Corporate Services LtdGCSL 65.2/100Favorable setup86% evidence LEADER 25.1/35 Income -19.4% · PAT 100% 81% evidence 18.2/25 ROA 11.5% · ROE 12.7% · GNPA — 68% evidence 1.9/20 P/BV 7.2× · P/BV÷ROE 0.57 100% evidence 20.0/20 RS sector 50.1% · RS bench 46.3% · 1Y 73.5%10 of 12 weeks ahead 100% evidence
Exact sum: 25.1 + 18.2 + 1.9 + 20 = 65.2 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
4Abans Financial Services LtdAFSL 64.7/100Mixed-positive evidence76% evidence ASLEEP 20.1/35 Income 100% · PAT -3.1% 71% evidence 14.3/25 ROA 3.6% · ROE 8.3% · GNPA — 68% evidence 16.8/20 P/BV 0.81× · P/BV÷ROE 0.1 100% evidence 13.5/20 RS sector 20.9% · RS bench -3.2% · 1Y -9%0 of 10 weeks ahead 70% evidence
Exact sum: 20.1 + 14.3 + 16.8 + 13.5 = 64.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Saraswati Commercial (India) Ltdthis pageZSARACOM 59.1/100Mixed-positive evidence67% evidence TURNING 24.8/35 Income 61.3% · PAT 75.5% 45% evidence 14.9/25 ROA 7.6% · ROE 8.9% · GNPA — 68% evidence 10.6/20 P/BV 1.21× · P/BV÷ROE 0.14 100% evidence 8.8/20 RS sector -17% · RS bench 4.7% · 1Y -5.3%2 of 6 weeks ahead 70% evidence
Exact sum: 24.8 + 14.9 + 10.6 + 8.8 = 59.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6BF Investment LtdBFINVEST 58.0/100Mixed-positive evidence73% evidence BREAKING OUT 21.8/35 Income 21% · PAT 26% 45% evidence 11.9/25 ROA 3% · ROE 3.6% · GNPA — 68% evidence 8.0/20 P/BV 0.2× · P/BV÷ROE 0.06 100% evidence 16.3/20 RS sector 7.7% · RS bench 4.1% · 1Y -6.2%10 of 12 weeks ahead 100% evidence
Exact sum: 21.8 + 11.9 + 8 + 16.3 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7CSL Finance LtdCSLFINANCE 57.5/100Mixed-positive evidence87% evidence 20.5/35 Income 19.1% · PAT 18.1% 67% evidence 22.0/25 ROA 9% · ROE 14.8% · GNPA 1.1% 95% evidence 12.0/20 P/BV 0.78× · P/BV÷ROE 0.05 100% evidence 3.0/20 RS sector -19.8% · RS bench -21.1% · 1Y -32.5%0 of 10 weeks ahead 100% evidence
Exact sum: 20.5 + 22 + 12 + 3 = 57.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
8STEL Holdings LtdSTEL 54.0/100Mixed-positive evidence76% evidence TURNING 26.0/35 Income 24.1% · PAT 26.6% 71% evidence 8.9/25 ROA 1.2% · ROE 1.2% · GNPA — 68% evidence 3.1/20 P/BV 0.66× · P/BV÷ROE 0.56 100% evidence 16.0/20 RS sector 20.4% · RS bench 17.7% · 1Y 42.2%6 of 10 weeks ahead 70% evidence
Exact sum: 26 + 8.9 + 3.1 + 16 = 54 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Mufin Green Finance LtdMUFIN 52.8/100Mixed-positive evidence78% evidence BREAKING OUT 22.4/35 Income 20.9% · PAT 42.1% 75% evidence 11.0/25 ROA 1.3% · ROE 6.7% · GNPA — 72% evidence 4.0/20 P/BV 4.55× · P/BV÷ROE 0.68 70% evidence 15.4/20 RS sector 21.1% · RS bench 17.8% · 1Y 48.7%10 of 12 weeks ahead 100% evidence
Exact sum: 22.4 + 11 + 4 + 15.4 = 52.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
10Balmer Lawrie Investment LtdBLIL 52.5/100Mixed-positive evidence82% evidence ASLEEP 15.9/35 Income 7.9% · PAT 4.1% 71% evidence 17.9/25 ROA 7.9% · ROE 12.7% · GNPA — 68% evidence 13.4/20 P/BV 1.09× · P/BV÷ROE 0.09 100% evidence 5.3/20 RS sector -4.5% · RS bench -7.7% · 1Y -16.4%1 of 12 weeks ahead 100% evidence
Exact sum: 15.9 + 17.9 + 13.4 + 5.3 = 52.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Bengal & Assam Company Ltd533095 52.0/100Mixed-positive evidence62% evidence ASLEEP 16.7/35 Income 6.4% · PAT 3.6% 55% evidence 12.8/25 ROA — · ROE 8.1% · GNPA — 34% evidence 15.8/20 P/BV 0.66× · P/BV÷ROE 0.08 100% evidence 6.7/20 RS sector -4.8% · RS bench -11% · 1Y -24.4%3 of 10 weeks ahead 70% evidence
Exact sum: 16.7 + 12.8 + 15.8 + 6.7 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12Dolat Algotech LtdDOLATALGO 51.8/100Mixed-positive evidence76% evidence ASLEEP 8.4/35 Income -23.9% · PAT -40.1% 71% evidence 17.8/25 ROA 8.5% · ROE 12.1% · GNPA — 68% evidence 17.2/20 P/BV 1.06× · P/BV÷ROE 0.09 100% evidence 8.4/20 RS sector -1% · RS bench -14.2% · 1Y -26.6%0 of 10 weeks ahead 70% evidence
Exact sum: 8.4 + 17.8 + 17.2 + 8.4 = 51.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
13PTC India Financial Services LtdPFS 51.5/100Mixed-positive evidence80% evidence ASLEEP 12.8/35 Income -22.7% · PAT -27.8% 81% evidence 16.4/25 ROA 6.5% · ROE 11% · GNPA — 68% evidence 16.4/20 P/BV 0.58× · P/BV÷ROE 0.05 100% evidence 5.9/20 RS sector -7.2% · RS bench -16.9% · 1Y -32.6%1 of 10 weeks ahead 70% evidence
Exact sum: 12.8 + 16.4 + 16.4 + 5.9 = 51.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
14Algoquant Fintech LtdALGOQUANT 51.1/100Mixed-positive evidence70% evidence TURNING 11.6/35 Income -0.4% · PAT 3.1% 71% evidence 20.1/25 ROA 12% · ROE 28.4% · GNPA — 68% evidence 4.5/20 P/BV 14.31× · P/BV÷ROE 0.5 70% evidence 14.9/20 RS sector 4.3% · RS bench 8.2% · 1Y 0.9%4 of 10 weeks ahead 70% evidence
Exact sum: 11.6 + 20.1 + 4.5 + 14.9 = 51.1 · Decision use: Price leads the evidence: RS versus the benchmark is 8.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
15Master Trust LtdMASTERTR 51.0/100Mixed-positive evidence76% evidence ASLEEP 11.1/35 Income -1.2% · PAT -4.5% 71% evidence 18.5/25 ROA 5.6% · ROE 17.3% · GNPA — 68% evidence 15.1/20 P/BV 1.24× · P/BV÷ROE 0.07 70% evidence 6.3/20 RS sector -19.9% · RS bench -23.4% · 1Y -51%6 of 12 weeks ahead 100% evidence
Exact sum: 11.1 + 18.5 + 15.1 + 6.3 = 51 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
16PTL Enterprises LtdPTL 50.2/100Mixed-positive evidence73% evidence ASLEEP 19.9/35 Income 0% · PAT 27.8% 45% evidence 13.7/25 ROA 3.3% · ROE 5.5% · GNPA — 68% evidence 8.0/20 P/BV 0.62× · P/BV÷ROE 0.11 100% evidence 8.6/20 RS sector 1.1% · RS bench -2% · 1Y -1.4%2 of 12 weeks ahead 100% evidence
Exact sum: 19.9 + 13.7 + 8 + 8.6 = 50.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17NBI Industrial Finance Company LtdNBIFIN 48.0/100Mixed-negative evidence65% evidence TURNING 22.0/35 Income 54.1% · PAT 60.7% 35% evidence 7.4/25 ROA 0.3% · ROE 0.3% · GNPA — 51% evidence 3.7/20 P/BV 0.2× · P/BV÷ROE 0.77 100% evidence 14.9/20 RS sector 3.6% · RS bench -0.2% · 1Y -23.8%4 of 12 weeks ahead 100% evidence
Exact sum: 22 + 7.4 + 3.7 + 14.9 = 48 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18Industrial & Prudential Investment Company LtdINDPRUD 47.8/100Mixed-negative evidence76% evidence ASLEEP 15.6/35 Income -25% · PAT 6.7% 71% evidence 15.4/25 ROA 7.3% · ROE 7.7% · GNPA — 68% evidence 5.9/20 P/BV 1.3× · P/BV÷ROE 0.17 100% evidence 10.9/20 RS sector -3.5% · RS bench 7% · 1Y -0.6%4 of 7 weeks ahead 70% evidence
Exact sum: 15.6 + 15.4 + 5.9 + 10.9 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19Finkurve Financial Services LtdFINKURVE 45.1/100Mixed-negative evidence73% evidence ASLEEP 19.2/35 Income 45.8% · PAT 19.1% 61% evidence 15.8/25 ROA 2.8% · ROE 13.3% · GNPA — 68% evidence 6.3/20 P/BV 5.02× · P/BV÷ROE 0.38 100% evidence 3.8/20 RS sector -34.4% · RS bench -28.6% · 1Y -45.1%2 of 11 weeks ahead 70% evidence
Exact sum: 19.2 + 15.8 + 6.3 + 3.8 = 45.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Authum Investment & Infrastructure LtdAIIL 42.2/100Mixed-negative evidence64% evidence TURNING 7.9/35 Income -34.6% · PAT -48.8% 62% evidence 14.9/25 ROA — · ROE 13.1% · GNPA — 34% evidence 5.7/20 P/BV 3.12× · P/BV÷ROE 0.24 100% evidence 13.7/20 RS sector 16.5% · RS bench -1.8% · 1Y -1.7%4 of 10 weeks ahead 70% evidence
Exact sum: 7.9 + 14.9 + 5.7 + 13.7 = 42.2 · Decision use: Price leads the evidence: RS versus the benchmark is -1.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
21PNB Gilts LtdPNBGILTS 41.2/100Mixed-negative evidence80% evidence TURNING 8.9/35 Income -5.3% · PAT -69.7% 81% evidence 9.7/25 ROA 0.7% · ROE 11.1% · GNPA — 68% evidence 15.0/20 P/BV 0.89× · P/BV÷ROE 0.08 100% evidence 7.6/20 RS sector -13.6% · RS bench -1.6% · 1Y -22.1%7 of 10 weeks ahead 70% evidence
Exact sum: 8.9 + 9.7 + 15 + 7.6 = 41.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
22Crest Ventures LtdCREST 41.1/100Mixed-negative evidence82% evidence FADING 8.6/35 Income -22.1% · PAT -46.9% 71% evidence 12.0/25 ROA 2.5% · ROE 3.8% · GNPA — 68% evidence 7.6/20 P/BV 0.82× · P/BV÷ROE 0.22 100% evidence 12.9/20 RS sector 4.1% · RS bench 0.8% · 1Y 0.4%4 of 12 weeks ahead 100% evidence
Exact sum: 8.6 + 12 + 7.6 + 12.9 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
23Grand Oak Canyons Distillery LtdGRANDOAK 41.1/100Mixed-negative evidence63% evidence TURNING 22.7/35 Income 100% · PAT 100% 48% evidence 4.0/25 ROA 0.1% · ROE 0% · GNPA — 72% evidence 3.6/20 P/BV 2.12× · P/BV÷ROE 212 70% evidence 10.8/20 RS sector 2% · RS bench -4.2% · 1Y 76.6%3 of 7 weeks ahead 70% evidence
Exact sum: 22.7 + 4 + 3.6 + 10.8 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24VLS Finance LtdVLSFINANCE 40.0/100Mixed-negative evidence67% evidence TURNING 13.3/35 Income -60.8% · PAT -54.4% 45% evidence 7.4/25 ROA 1% · ROE 0.9% · GNPA — 68% evidence 4.8/20 P/BV 0.38× · P/BV÷ROE 0.4 100% evidence 14.5/20 RS sector 9.2% · RS bench 1.6% · 1Y 6.9%3 of 10 weeks ahead 70% evidence
Exact sum: 13.3 + 7.4 + 4.8 + 14.5 = 40 · Decision use: Price leads the evidence: RS versus the benchmark is 1.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
25Capital India Finance LtdCIFL 39.9/100Thin evidence · provisional55% evidence ASLEEP 17.5/35 Income -8.5% · PAT 100% 45% evidence 8.7/25 ROA 1.7% · ROE -9% · GNPA — 68% evidence 9.2/20 P/BV 1.21× · P/BV÷ROE — 40% evidence 4.5/20 RS sector -17.4% · RS bench -32.6% · 1Y -44.5%0 of 10 weeks ahead 70% evidence
Exact sum: 17.5 + 8.7 + 9.2 + 4.5 = 39.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
26The Investment Trust of India LtdTHEINVEST 37.1/100Mixed-negative evidence67% evidence ASLEEP 13.1/35 Income -19.4% · PAT -24.4% 45% evidence 11.4/25 ROA 2.7% · ROE 4.1% · GNPA — 68% evidence 8.6/20 P/BV 0.69× · P/BV÷ROE 0.17 70% evidence 4.0/20 RS sector -14.5% · RS bench -17.8% · 1Y -43.2%1 of 12 weeks ahead 100% evidence
Exact sum: 13.1 + 11.4 + 8.6 + 4 = 37.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
27Nalwa Sons Investments LtdNSIL 33.4/100Adverse evidence63% evidence ASLEEP 16.2/35 Income -19.2% · PAT 23.3% 48% evidence 5.9/25 ROA 0.3% · ROE 0.3% · GNPA — 72% evidence 5.0/20 P/BV 0.19× · P/BV÷ROE 0.56 70% evidence 6.3/20 RS sector -6.9% · RS bench -12.9% · 1Y -20.1%0 of 10 weeks ahead 70% evidence
Exact sum: 16.2 + 5.9 + 5 + 6.3 = 33.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Prime Securities LtdPRIMESECU 32.3/100Adverse evidence86% evidence ASLEEP 8.8/35 Income 14.4% · PAT -80% 81% evidence 13.1/25 ROA 4.6% · ROE 4.1% · GNPA — 68% evidence 3.1/20 P/BV 3.66× · P/BV÷ROE 0.9 100% evidence 7.3/20 RS sector -0.2% · RS bench -3.2% · 1Y -4%0 of 12 weeks ahead 100% evidence
Exact sum: 8.8 + 13.1 + 3.1 + 7.3 = 32.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
29Oswal Green Tech LtdOSWALGREEN 32.2/100Adverse evidence64% evidence ASLEEP 15.2/35 Income -19.7% · PAT -80% 19% evidence 8.0/25 ROA 1.1% · ROE 1.5% · GNPA — 68% evidence 8.0/20 P/BV 0.23× · P/BV÷ROE 0.16 100% evidence 1.0/20 RS sector -29.3% · RS bench -32.2% · 1Y -52.5%0 of 12 weeks ahead 100% evidence
Exact sum: 15.2 + 8 + 8 + 1 = 32.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
30Systematix Corporate Services LtdSYSTMTXC 29.4/100Adverse evidence70% evidence ASLEEP 9.8/35 Income 10.9% · PAT -71.7% 71% evidence 12.2/25 ROA 3% · ROE 4.6% · GNPA — 68% evidence 4.3/20 P/BV 2.66× · P/BV÷ROE 0.58 70% evidence 3.1/20 RS sector -38.6% · RS bench -39.3% · 1Y -50.2%0 of 10 weeks ahead 70% evidence
Exact sum: 9.8 + 12.2 + 4.3 + 3.1 = 29.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
31Dhunseri Investments LtdDHUNINV 28.2/100Adverse evidence61% evidence 13.7/35 Income -25.9% · PAT -66.7% 29% evidence 4.8/25 ROA -0.5% · ROE 0.7% · GNPA — 68% evidence 6.0/20 P/BV 0.19× · P/BV÷ROE 0.29 100% evidence 3.7/20 RS sector -34.8% · RS bench -23.8% · 1Y -43.5%1 of 7 weeks ahead 70% evidence
Exact sum: 13.7 + 4.8 + 6 + 3.7 = 28.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
32Spice Lounge Food Works LtdSPICELOUNG 41.2/100Thin evidence · provisional34% evidence 17.5/35 Income — · PAT — 0% evidence 10.9/25 ROA — · ROE 5.2% · GNPA — 26% evidence 3.2/20 P/BV 18.93× · P/BV÷ROE 3.64 70% evidence 9.6/20 RS sector 0.7% · RS bench -8.4% · 1Y -19.3%2 of 12 weeks ahead to 2026-03-08 70% evidence
Exact sum: 17.5 + 10.9 + 3.2 + 9.6 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
33Eraaya Lifespaces LtdEBIX 39.5/100Thin evidence · provisional22% evidence 17.5/35 Income — · PAT — 0% evidence 9.3/25 ROA — · ROE -809% · GNPA — 26% evidence 9.2/20 P/BV 6.36× · P/BV÷ROE — 10% evidence 3.5/20 RS sector -34.1% · RS bench -39.5% · 1Y -48.5%8 of 12 weeks ahead to 2026-03-08 70% evidence
Exact sum: 17.5 + 9.3 + 9.2 + 3.5 = 39.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. Financial companies use P/BV÷ROE and asset quality; PEG, industrial OPM and ROCE are excluded. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

15 · Frequently asked questions

Frequently asked questions

What is Saraswati Commercial (India) Ltd's share price today?

Saraswati Commercial (India) Ltd trades at ₹12,400, −5.3% over the past year. The company is valued at ₹1,337 Cr. The stock sits at 58% of its 52-week range of ₹9,209–₹14,743, +7.1% versus its 200-day average. On the tape, the price is in a downtrend, 54 weeks in. — as of 31 July 2026.

What were Saraswati Commercial (India) Ltd's latest quarterly results?

Saraswati Commercial (India) Ltd reported total income of ₹−16.0 Cr and a net loss of ₹16.0 Cr for the Mar 26 quarter. Earnings per share were ₹−148.83. The net margin was 100.0%, 11.5 pp higher than a year earlier. — as of 31 July 2026.

What is Saraswati Commercial (India) Ltd's revenue?

Saraswati Commercial (India) Ltd reported revenue of ₹−16.0 Cr in the Mar 26 quarter. For the full FY26 fiscal year, revenue was ₹121 Cr (+61.3%). Over the last 10 years revenue compounded at 20.3% a year. — as of 31 July 2026.

What is Saraswati Commercial (India) Ltd's profit?

Saraswati Commercial (India) Ltd earned ₹−16.0 Cr of net profit in the Mar 26 quarter. Full-year FY26 profit was ₹92.0 Cr. The net margin ran 100.0% in the latest quarter. — as of 31 July 2026.

What is Saraswati Commercial (India) Ltd's market cap?

Saraswati Commercial (India) Ltd's market capitalisation is ₹1,337 Cr at a share price of ₹12,400. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.

What is Saraswati Commercial (India) Ltd's P/BV ratio?

Saraswati Commercial (India) Ltd trades at a P/BV of 1.2×, at the 70th percentile of its own 7-year range, against a long-run median of 0.9×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.

Does Saraswati Commercial (India) Ltd pay a dividend?

No — Saraswati Commercial (India) Ltd has recorded a dividend payout of 0% of profit in each of its last 13 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.

Is Saraswati Commercial (India) Ltd overvalued?

On its own history, Saraswati Commercial (India) Ltd looks expensive against its own history: its P/BV of 1.2× sits at the 70th percentile of its 7-year range (long-run median 0.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.

How is Saraswati Commercial (India) Ltd performing?

Saraswati Commercial (India) Ltd is in a downtrend, 54 weeks in. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 5 weeks. This describes what the data did, not a rating. — as of 31 July 2026.

Is Saraswati Commercial (India) Ltd in an uptrend?

No — the price is in a downtrend (week 54 of stage 4), trading +7.1% versus its 200-day average and at 58% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.

Is Saraswati Commercial (India) Ltd beating the market?

On recent form, yes — Saraswati Commercial (India) Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 5 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 9.0 years the stock moved +1,47,519% against the NIFTY 500's +171% — ahead of the index over the full window. — as of 31 July 2026.

Will Saraswati Commercial (India) Ltd's share price go up?

This page publishes no price forecast for Saraswati Commercial (India) Ltd. What it measures instead: the share price is ₹12,400, the price is in a downtrend 54 weeks in. Its P/BV of 1.2× sits at the 70th percentile of its own 7-year range. — as of 31 July 2026.

Who owns Saraswati Commercial (India) Ltd?

Promoters hold 74.9% of Saraswati Commercial (India) Ltd, foreign institutions null%, domestic institutions null% and the public 25.1% (latest quarter). The biggest move on the register over the last two years: Promoters added 2.5 points over 8 quarters. — as of 31 July 2026.

Is Saraswati Commercial (India) Ltd's loan book healthy?

We do not hold quarterly loan-book quality numbers for Saraswati Commercial (India) Ltd, so this page says that plainly. The cleanest available reads are revenue growth (+61.3% in FY26) and the net margin on it (100.0%) — as of 31 July 2026.

Where is Saraswati Commercial (India) Ltd in its business cycle?

Saraswati Commercial (India) Ltd's FY26 net margin was 76.0%, against a 13-year band of −1,000.0%–100.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 100.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.

What could break the Saraswati Commercial (India) Ltd story?

The sharpest disagreement: annual EPS moved +72.8% against a −5.3% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.

Is Saraswati Commercial (India) Ltd a stock worth studying right now?

This is not investment advice. The machine read: Saraswati Commercial (India) Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI